LOSS OF EARLY GAINS IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL GOAL ATTAINMENT AMONG HIGH RISK PATIENTS  by Foody, Joanne M. et al.
A136.E1274
JACC March 9, 2010
Volume 55, issue 10A
 QUALITY OF CARE AND OUTCOMES ASSESSMENT 
LOSS OF EARLY GAINS IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL GOAL ATTAINMENT AMONG HIGH 
RISK PATIENTS
ACC Poster Contributions
Georgia World Congress Center, Hall B5
Monday, March 15, 2010, 9:30 a.m.-10:30 a.m.
Session Title: Diabetes, Lipids, Obesity
Abstract Category: Outcomes Assessment
Presentation Number: 1137-156
Authors: Joanne M. Foody, Shiva Sajjan, Henry Hu, Dena R. Ramey, David Neff, Andrew M. Tershakovec, Joanne E. Tomassini, Kaan Tunceli, Merck & 
Co., Inc., North Wales, PA
Background: The 2006 ACC/AHA Secondary Prevention Statement suggests that treating high risk patients with CHD or atherosclerotic vascular 
disease (AVD) to LDL-C <70 mg/dL is reasonable. This retrospective study cross-sectionally examined LDL-C goal attainment trends in high risk 
patients treated and untreated with lipid lowering therapy (LLT) from Jan 1 2004 to Aug 31 2008 in a large, national managed care (MC) database.
Methods: CHD or AVD patients with at least one LDL-C test during Jan 1 2004 to Aug, 31 2008 (n=284,915) were identified through a MC 
database that links enrollment data, medical and prescription drug claims and outpatient laboratory test results at a patient level for an employed, 
commercially insured population with dependents. Average LDL-C values and percentage of patients not achieving LDL-C goal (those with LDL-C 
≥70 mg/dL) were obtained by averaging patient level LDL-C values for each month. A linear trend analysis with first-order autocorrelated errors was 
conducted.
Results: The proportion of patients treated with LLT gradually increased from 59.5% in Jan 2004 to 74.2% in Aug 2008. Mean LDL-C values in 
LLT-treated patients decreased from 100.0 to 95.9 mg/dL, whereas LDL-C remained relatively constant in untreated patients (113.8 - 114.7 mg/
dL) during this period. Among untreated patients, the percentage with LDL-C ≥70 mg/dL remained relatively stable throughout the period (92.9% in 
Jan 2004 and 93.0% in Aug 2008; range 89.8%-94.1%). In treated patients, the percentage with LDL-C ≥70 mg/dL decreased from 87.5% in Jan 
2004 to 73.8% in Dec 2006 (range 71.8%-87.5%; linear trend, p <0.0001), and then generally plateaued between Jan 2007 (79.6%) and Aug 2008 
(76.2%) (range: 76.2%-79.6%; linear trend, p=0.0014).
Conclusion: The proportion of LLT-treated high risk patients with CHD or AVD who achieve LDL-C <70 mg/dL levels has increased since 2004, 
though initial upward trends in goal attainment have flattened since 2007 and a large proportion of these patients still do not meet this goal. 
Additionally, 1 out of 4 high risk patients otherwise eligible for LLT remain untreated. These data suggest the need for renewed efforts to support 
guideline-based LDL-C lowering in high risk patients.
